The application of CD19-targeted CAR-T cells has proven highly successful in treating B-cell malignancies, achieving complete remission in many patients with acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) (164). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.